UCB announced today its consolidated full year 2009 financial results. 2009 was a year of execution and delivery.
The company reached a turning point through new drug approvals and launches as well as the transformation of its organization. UCB achieved major development and regulatory milestones and reduced and refinanced the existing debt with a new financing structure reflecting an improved maturity profile. With all this, UCB created a strong basis for sustainable future growth.
“UCB is progressing to become a patient-centric global biopharmaceutical leader as we delivered three new medicines Cimzia, Vimpat and Neupro in five indications to patients living with serious diseases of the central nervous system and immunology. Our financial results are on track and our debt is successfully re-financed.
Another pillar of UCB’s sustainable growth will be the realization of the full potential of our core products: Cimzia, which we expect to reach peak sales of at least 1.5 billion Euro, Vimpat with expected peak sales of at least 1.2 billion Euro and Neupro with estimated peak sales of at least 400 million Euro,” said Roch Doliveux, Chief Executive Officer, UCB. “With the recent appointment of Ismail Kola as Executive Vice President, UCB & President of UCB NewMedicinesâ„¢, we have underlined our commitment to a successful breakthrough phase bringing new medicines to the development pipeline and fostering further sustainable growth.”